Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00038298 | A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate | PHASE2 | COMPLETED | 53 | — | — | Apr 1, 2002 | May 1, 2004 | Jan 21, 2011 | - | — |
| Arm | Type | Description |
|---|---|---|
| 50 mg | EXPERIMENTAL | 50 mg 3 times weekly |
| 400 mg | EXPERIMENTAL | 400 mg 3 times weekly |
| 200 mg | EXPERIMENTAL | 200 mg 3 times weekly |
| Placebo | PLACEBO_COMPARATOR | Placebo comparator associated with each active arm. (3:1 active vs placebo) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo given 3 times weekly |
| AMG 719 | DRUG | 50 mg 3 times weekly |
| AGM 719 | DRUG | 200 mg 3 times weekly |
| placebo to AMG 719 | DRUG | Placebo dose given 3 times weekly |
* Men or women, at least 18 years of age at screening * Diagnosed with Rheumatoid Arthritis, with a disease duration of at least 24 weeks, receiving methotrexate, and having no recent history of substance or alcohol abuse